Overview
- SK Capital’s affiliate signed a definitive agreement to invest in Swixx BioPharma, valuing the company at more than €1.5 billion.
- Co-founders Stuart Swanson and Petr Němec, CEO Jean‑Michel Lespinasse and CFO Petr Pipal will retain significant stakes, with HBM Healthcare Investments and Mérieux Equity Partners staying on as shareholders.
- Ares Credit funds provided committed debt financing, and advisors included Rothschild & Co, Jefferies, Centerview Partners, KPMG, ClearView, EY, BCG, Bär & Karrer, Kirkland & Ellis, and Walder Wyss.
- Swixx operates in 45 countries across Central and Eastern Europe, Greece, Eurasia and CIS, the Middle East and Latin America, and projects sales to exceed €1.3 billion in 2026 with roughly 1,600 employees by end‑2025.
- The companies say the capital will accelerate growth and global expansion of Swixx’s outsourced commercialization services, with SK Capital managing about $10 billion in assets as of year‑end 2024.